1
TITLE: Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
AUTHORS: Fritz Offner; Olga Samoilova; Evgenii Osmanov; Hyeon Seok Eom; Max S Topp; Joao Raposo; Viacheslav Pavlov; Deborah Ricci; Shalini Chaturvedi; Eugene Zhu; Helgi van de Velde; Christopher Enny; Aleksandra Rizo; Burhan Ferhanoglu;
PUBLISHED: 2015, SOURCE: BLOOD, VOLUME: 126, ISSUE: 16
INDEXED IN: Scopus WOS CrossRef
2
TITLE: Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab
AUTHORS: Bertrand Coiffier; Weimin M Li; Erin D Henitz; Jayaprakash D Karkera; Reyna Favis; Dana Gaffney; Alice Shapiro; Panteli Theocharous; Yusri A Elsayed; Helgi van de Velde; Michael E Schaffer; Evgenii A Osmanov; Xiaonan N Hong; Adriana Scheliga; Jiri Mayer; Fritz Offner; Simon Rule; Adriana Teixeira; Joanna Romejko Jarosinska; Sven de Vos; Michael Crump; Ofer Shpilberg; Pier Luigi Zinzani; Andrew Cakana; Dixie Lee Esseltine; George Mulligan; Deborah Ricci; ...More
PUBLISHED: 2013, SOURCE: CLINICAL CANCER RESEARCH, VOLUME: 19, ISSUE: 9
INDEXED IN: Scopus WOS CrossRef